ImmunoPrecise Antibodies Inc (TSE:IPA) (OTCMKTS:IPATF) is rapidly bringing on biopharmaceutical clients with its B-cell and phage display platforms.
The antibody discovery company offers antibody development services that its clients can then use as treatments. Phages, a type of virus that infects bacteria with a given gene and replicates inside them, are a means of achieving that goal. B-cells are a white blood cell that produces antibodies.
Ligand Pharmaceuticals, Ablexis, Trianni, and Harbour BioMed, among others, are getting in on the action. IPA’s B-cell and phage display programs have been launched in seven of its nine client platforms, and one client is running three programs simultaneously.
READ: ImmunoPrecise subsidiary U-Protein Express clinches license from Stanford University to manufacture protein
What’s unique about IPA’s phages is that they’re easily adapted to be used in transgenic animals, which have been genetically modified to Express human antibodies. Companies can insert protein-producing genes into different phages to see which ones produce a result that binds with disease target molecules.
Trianni, for example, has developed mice that replicate the full antibody repitoire found in humans. That means the mice can be used, at a much faster rate, to identify potential antibody therapies for human use.
"This unprecedented growth in the demand and use of alternative transgenic species and strains is a client solicitation that IPA has been anticipating, and is fully prepared to respond to," CEO Jennifer Bath said. "The requests have been well distributed across our locations worldwide and continue to engage all three of our global, antibody manufacturing sites."
IPA operates in Victoria, British Columbia and through its subsidiary U-Protein Express BV in two cities in the Netherlands. Its stock was flat at C$0.70 in Toronto and down 1.2% to US$0.51 on OTC markets.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel